|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |review |
 |
(a) from Vineis et al, IARC Scie. Publ. No.
148, 1999 1999 (b) from Hopper et al, 1999 (c) theoretical maximum reduction in risk of lung cancer due to preventive action (d) theoretical benefit, based on the BCPT trial with a 45% benefit, and the Raloxifene trial with a 76% benefit |